Diisopropylethylamine → (S)-3-(2-((S)-1-cyclopropylethylamino)-5-fluoropyrimidin-4-yl)-4-phenyloxazolidin-2-one
反応式
Cl[C:2]1[N:7]=[C:6]([N:8]2[C@@H:12]([C:13]3[CH:18]=[CH:17][CH:16]=[CH:15][CH:14]=3)[CH2:11][O:10][C:9]2=[O:19])[C:5]([F:20])=[CH:4][N:3]=1.[CH:21]1([C@@H:24]([NH2:26])[CH3:25])[CH2:23][CH2:22]1.CCN(C(C)C)C(C)C>CS(C)=O.O>[CH:21]1([C@@H:24]([NH:26][C:2]2[N:7]=[C:6]([N:8]3[C@@H:12]([C:13]4[CH:18]=[CH:17][CH:16]=[CH:15][CH:14]=4)[CH2:11][O:10][C:9]3=[O:19])[C:5]([F:20])=[CH:4][N:3]=2)[CH3:25])[CH2:23][CH2:22]1参加物
6
反応物 3
生成物 1
試薬・触媒・溶媒 2
反応条件
- 温度
- 127.5 °C
実験手順
A mixture of (S)-3-(2-chloro-5-fluoropyrimidin-4-yl)-4-phenyloxazolidin-2-one (40 mg, 0.136 mmol), (S)-1-cyclopropylethanamine (34.8 mg, 0.409 mmol), Hunig's Base (0.119 mL, 0.681 mmol) in DMSO (0.4 mL) was heated under argon at 105-115° C. for ˜18 hrs (alternative: 120-135° C. for ˜90 min). Then mixture was allowed to cool to room temperature. The mixture was diluted with DMSO and water (˜10 vol. % of DMSO), filtered through a syringe filter and purified by reverse phase HPLC. Selected fractions were collected and lyophilized providing (S)-3-(2-((S)-1-cyclopropylethylamino)-5-fluoropyrimidin-4-yl)-4-phenyloxazolidin-2-one (26 mg) as a white solid as its trifluoroacetic acid salt.
後処理
- temperatureto cool to room temperature
- filtrationfiltered through a syringe
- filtrationfilter
- custompurified by reverse phase HPLC
- customSelected fractions were collected
出典と根拠
- ORDレコード
- ord-b92f1f1d26f24e7687b7631026f216cd
- 出典データセット
- uspto-grants-2015_02
- 特許番号
- US08957068B2
反応ノート
読み込み中…